Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from B. Riley

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report)'s stock had its "buy" rating reiterated by B. Riley in a note issued to investors on Wednesday,Benzinga reports. They currently have a $24.00 target price on the stock, up from their prior target price of $21.00. B. Riley's price objective indicates a potential upside of 68.78% from the company's current price. B. Riley also issued estimates for Eton Pharmaceuticals' Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.14 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

A number of other equities analysts also recently weighed in on ETON. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded down $0.56 during trading on Wednesday, hitting $14.22. The company's stock had a trading volume of 223,652 shares, compared to its average volume of 159,818. The stock's fifty day moving average is $15.58 and its 200 day moving average is $11.63. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The stock has a market capitalization of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37.

Remove Ads

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. On average, research analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the third quarter worth $54,000. Tower Research Capital LLC TRC purchased a new stake in Eton Pharmaceuticals during the 4th quarter worth $86,000. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Jefferies Financial Group Inc. purchased a new position in Eton Pharmaceuticals in the fourth quarter valued at about $133,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth about $147,000. Hedge funds and other institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.